SLN
Silence Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$19.58
+125.58%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 275.98x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 31.63x
- Price / sales
- 1981.11x
- Price / cash flow
- -28.78x
Enterprise value
- Enterprise value
- $1.1B
- EV / sales
- 1863.99x
- EV / EBITDA
- -18.99x
- EV / EBIT
- -17.13x
- Market cap
- $1.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026